Cargando…

Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: direct oral anticoagulants (DOACs) are a well-known alternative to conventional antagonist of vitamin-K (avK) and have emerged as the preferred choice due to their safety and efficacy profile. However, immune modulating drugs as cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, F, Casanova, A, Simone, S, Pellegrino, P L, D'arienzo, G, Brunetti, N D, Pesce, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207264/
http://dx.doi.org/10.1093/europace/euad122.211
_version_ 1785046414153220096
author Santoro, F
Casanova, A
Simone, S
Pellegrino, P L
D'arienzo, G
Brunetti, N D
Pesce, F
author_facet Santoro, F
Casanova, A
Simone, S
Pellegrino, P L
D'arienzo, G
Brunetti, N D
Pesce, F
author_sort Santoro, F
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: direct oral anticoagulants (DOACs) are a well-known alternative to conventional antagonist of vitamin-K (avK) and have emerged as the preferred choice due to their safety and efficacy profile. However, immune modulating drugs as cyclosporine and tacrolimus, commonly used for transplant recipients, may interfere with DOACs. Aim of this study: evaluate safety and efficacy profile of direct oral anticoagulants (DOACs) compared to warfarin in kidney transplant recipients (KTRs) treated with immune modulating agents. METHODS: a multi-center study from 4 Italian hospitals enrolling KTRs on DOACs or avK was carried out. Sixty-nine patients on DOACs were compared with fifty patients on avK with mean estimated glomerular filtrate rate (eGFR) > 45 mL/min. Clinical follow-up and serial evaluation of renal function and serum levels of immune modulating drugs during 24 months follow-up (FU) was performed. RESULTS: Mean age of DOACs patients was 67±9 and mean eGFR was57±20 mL/min. Immune-modulating therapy included tacrolimus (n=47, 71%), cyclosporin (n=13, 20%), everolimus (n=10, 7%) and sirolimus (n=4, 6%). There were no changes in Tacrolimus and Cyclosporin serum levels following 14 days therapy with DOACs (+0.5 ±2 and +28 ±31, p=0.52, 0.90, respectively) and only a patient treated with dabigatran 150 mg required a dose adjustment. Levels of Tacrolimus and cyclosporin were stable at serial evaluation during follow-up. At long-term follow-up, there were no thromboembolic events among patients treated with DOACs or avK and no differences in term of mayor bleeding (5.8% vs 4% p=0.99). There was no difference in term of eGFR decline from start therapy to 24 months FU between DOACs or avK therapy (-3.9±1 vs -3.8±2 p=0.82) (FIGURE 1). CONCLUSION: DOACs are a potential therapeutic option among patients with kidney transplant recipients treated with immune modulating drugs. Careful evaluation of immunomodulating agent levels during the first two week of therapy should be recommended. No difference in term of bleeding, renal function decline was found when comparing with avK therapy. [Figure: see text]
format Online
Article
Text
id pubmed-10207264
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102072642023-05-25 Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study Santoro, F Casanova, A Simone, S Pellegrino, P L D'arienzo, G Brunetti, N D Pesce, F Europace 10.5.1 - Oral Anticoagulation FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: direct oral anticoagulants (DOACs) are a well-known alternative to conventional antagonist of vitamin-K (avK) and have emerged as the preferred choice due to their safety and efficacy profile. However, immune modulating drugs as cyclosporine and tacrolimus, commonly used for transplant recipients, may interfere with DOACs. Aim of this study: evaluate safety and efficacy profile of direct oral anticoagulants (DOACs) compared to warfarin in kidney transplant recipients (KTRs) treated with immune modulating agents. METHODS: a multi-center study from 4 Italian hospitals enrolling KTRs on DOACs or avK was carried out. Sixty-nine patients on DOACs were compared with fifty patients on avK with mean estimated glomerular filtrate rate (eGFR) > 45 mL/min. Clinical follow-up and serial evaluation of renal function and serum levels of immune modulating drugs during 24 months follow-up (FU) was performed. RESULTS: Mean age of DOACs patients was 67±9 and mean eGFR was57±20 mL/min. Immune-modulating therapy included tacrolimus (n=47, 71%), cyclosporin (n=13, 20%), everolimus (n=10, 7%) and sirolimus (n=4, 6%). There were no changes in Tacrolimus and Cyclosporin serum levels following 14 days therapy with DOACs (+0.5 ±2 and +28 ±31, p=0.52, 0.90, respectively) and only a patient treated with dabigatran 150 mg required a dose adjustment. Levels of Tacrolimus and cyclosporin were stable at serial evaluation during follow-up. At long-term follow-up, there were no thromboembolic events among patients treated with DOACs or avK and no differences in term of mayor bleeding (5.8% vs 4% p=0.99). There was no difference in term of eGFR decline from start therapy to 24 months FU between DOACs or avK therapy (-3.9±1 vs -3.8±2 p=0.82) (FIGURE 1). CONCLUSION: DOACs are a potential therapeutic option among patients with kidney transplant recipients treated with immune modulating drugs. Careful evaluation of immunomodulating agent levels during the first two week of therapy should be recommended. No difference in term of bleeding, renal function decline was found when comparing with avK therapy. [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207264/ http://dx.doi.org/10.1093/europace/euad122.211 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 10.5.1 - Oral Anticoagulation
Santoro, F
Casanova, A
Simone, S
Pellegrino, P L
D'arienzo, G
Brunetti, N D
Pesce, F
Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
title Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
title_full Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
title_fullStr Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
title_full_unstemmed Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
title_short Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
title_sort immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
topic 10.5.1 - Oral Anticoagulation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207264/
http://dx.doi.org/10.1093/europace/euad122.211
work_keys_str_mv AT santorof immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy
AT casanovaa immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy
AT simones immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy
AT pellegrinopl immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy
AT darienzog immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy
AT brunettind immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy
AT pescef immunemodulatingdrugsandoralanticoagulationinkidneytransplantrecipientscomparisonofdirectoralanticoagulantsversusantagonistofvitaminkresultsfromamulticenterprospectivestudy